{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:12:46Z","timestamp":1779289966458,"version":"3.51.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.566160","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T11:54:00Z","timestamp":1604058840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial"],"prefix":"10.3389","volume":"7","author":[{"given":"James Cheng-Chung","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Kai","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pui-Ying","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Xian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<;1346::AID-ANR18>;3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.21563","article-title":"Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial","volume":"54","author":"Haibel","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/rmdopen-2019-000942","article-title":"Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials","volume":"5","author":"Curtis","year":"2019","journal-title":"RMD Open."},{"key":"B8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40744-020-00214-7","article-title":"Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE","volume":"7","author":"Landew\u00e9","year":"2020","journal-title":"Rheumatol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3899\/jrheum.131003","article-title":"The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial","volume":"41","author":"van der Heijde","year":"2014","journal-title":"J Rheumatol."},{"key":"B11","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/rheumatology\/kem294","article-title":"Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance","volume":"47","author":"Wailoo","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11280","article-title":"Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation","volume":"11","author":"McLeod","year":"2007","journal-title":"Health Technol Assess."},{"key":"B16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40744-020-00197-5","article-title":"Improvement of function and its determinants in a group of axial spondyloarthritis patients treated with TNF inhibitors: a real-life study","volume":"7","author":"Lubrano","year":"2020","journal-title":"Rheumatol Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s10067-017-3693-7","article-title":"Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis","volume":"36","author":"Ungprasert","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/rmdopen-2019-001079","article-title":"Treatment retention of infliximab and etanercept originators vs. their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics na\u00efve patients with spondyloarthritis","volume":"5","author":"Lindstr\u00f6m","year":"2019","journal-title":"RMD Open."},{"key":"B19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","article-title":"To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. one-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry","volume":"78","author":"Glintborg","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40259-018-0283-4","article-title":"Efficacy and safety outcomes for originator TNF inhibitors and biosimilars in rheumatoid arthritis and psoriasis trials: a systematic literature review","volume":"32","author":"Moots","year":"2018","journal-title":"BioDrugs."},{"key":"B21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","article-title":"Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS)","volume":"40","author":"Baraliakos","year":"2020","journal-title":"Clin Drug Investig."},{"key":"B22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/art.22236","article-title":"Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study","volume":"55","author":"Cantini","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<;1876::AID-ART326>;3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40265-014-0246-0","article-title":"Treat-to-target in spondyloarthritis: implications for clinical trial designs","volume":"74","author":"Wei","year":"2014","journal-title":"Drugs."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"Update of the American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network recommendations for the treatment ofankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3899\/jrheum.150389","article-title":"Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study","volume":"42","author":"Heinonen","year":"2015","journal-title":"J Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","article-title":"Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis","volume":"47","author":"Deodhar","year":"2017","journal-title":"Semin Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/PPA.S121032","article-title":"Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis","volume":"11","author":"Bolge","year":"2017","journal-title":"Patient Prefer Adherence."},{"key":"B35","first-page":"34","article-title":"Retention on anti-tumour necrosis factor therapy: the Waikato experience","volume":"128","author":"Ip","year":"2015","journal-title":"N Z Med J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e000762","DOI":"10.1136\/rmdopen-2018-000762","article-title":"Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study","volume":"4","author":"Lindstr\u00f6m","year":"2018","journal-title":"RMD Open."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e14620","DOI":"10.1097\/MD.0000000000014620","article-title":"A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"B39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3109\/14397595.2014.972495","article-title":"Local infliximab injection of sacroiliac joints in non-radiographic axial spondyloarthritis: impact on clinical and magnetic resonance imaging parameters of disease activity","volume":"25","author":"Soliman","year":"2015","journal-title":"Mod Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/art.20790","article-title":"ASsessment in ankylosing spondylitis International working group\/spondylitis association of America recommendations for conducting clinical trials in ankylosing spondylitis","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","article-title":"Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases","volume":"32","author":"Mok","year":"2013","journal-title":"Clin Rheumatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00296-019-04288-7","article-title":"Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis","volume":"39","author":"Senabre Gallego","year":"2019","journal-title":"Rheumatol Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1208\/s12248-018-0219-4","article-title":"Investigation of the mechanism of therapeutic protein-drug interaction between methotrexate and golimumab, an Anti-TNF\u03b1 monoclonal antibody","volume":"20","author":"Wang","year":"2018","journal-title":"AAPS J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12891-015-0620-4","article-title":"Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab","volume":"16","author":"Lorenzin","year":"2015","journal-title":"BMC Musculoskelet Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3899\/jrheum.170666","article-title":"The sex influence on response to tumor necrosis factor-\u03b1 inhibitors and remission in axial spondyloarthritis","volume":"45","author":"Lubrano","year":"2018","journal-title":"J Rheumatol."},{"key":"B46","first-page":"857","article-title":"Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the monitorNet database","volume":"31","author":"Scir\u00e8","year":"2013","journal-title":"Clin Exp Rheumatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.566160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T11:54:03Z","timestamp":1604058843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.566160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":46,"alternative-id":["10.3389\/fmed.2020.566160"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.566160","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"article-number":"566160"}}